Anika Revamps Orthovisc Knee Trials In Hopes Of Catching Rivals In Footrace
This article was originally published in The Gray Sheet
Executive Summary
Anika Therapeutics will apply for an investigational device exemption from FDA this quarter to begin supplemental clinical trials in support of its rejected premarket approval application for Orthovisc hyalauronic-acid (HA) injectable treatment for osteoarthritis of the knee.